BHC Overzicht aandelen Bausch Health Companies Inc. is een gediversifieerd bedrijf in farmaceutische specialiteiten en medische apparatuur in de Verenigde Staten en internationaal. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
Bausch Health Companies Inc. Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Bausch Health Companies Historische aandelenkoersen Huidige aandelenkoers US$7.53 52 Week Hoogtepunt US$11.46 52 Week Laag US$3.96 Bèta 0.69 1 maand verandering -5.52% 3 maanden verandering -6.23% 1 Jaar Verandering -1.70% 3 jaar verandering -73.28% 5 jaar verandering -74.83% Verandering sinds IPO 1,406.00%
Recent nieuws en updates
Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors Dec 03
Bausch Health Companies Inc. Appoints Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D Dec 02
Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada Nov 19
Price target increased by 7.1% to US$8.57 Nov 03
Forecast breakeven date pushed back to 2025 Nov 03
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 01 Meer updates bekijken
Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors Dec 03
Bausch Health Companies Inc. Appoints Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D Dec 02
Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada Nov 19
Price target increased by 7.1% to US$8.57 Nov 03
Forecast breakeven date pushed back to 2025 Nov 03
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 01
Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA Oct 28
There's No Escaping Bausch Health Companies Inc.'s (NYSE:BHC) Muted Revenues Despite A 28% Share Price Rise Oct 10
Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 10
Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely Sep 19
Price target decreased by 18% to US$7.79 Sep 14
Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel Sep 11
Executive VP & General Counsel exercised options and sold US$318k worth of stock Sep 10
Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28% Aug 06
Price target decreased by 11% to US$8.36 Aug 04
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 02
Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024 Aug 01
2 Red Alerts On Bausch Health Companies Jul 25 Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma
Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 12
Price target decreased by 7.7% to US$9.56 Jul 10
The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25% May 21
Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024 May 18
Bausch Health Companies Inc. Approves Directorate Appointments May 16
Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results May 07
First quarter 2024 earnings: EPS misses analyst expectations May 03
Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan Apr 13
Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 12
Price target increased by 10% to US$10.33 Apr 05
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults Apr 03
Insufficient new directors Apr 01
Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma Mar 06
Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation Feb 24
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 23
Consensus EPS estimates fall from profit to US$0.03 loss Feb 22
Bausch Health Companies Inc., Annual General Meeting, May 14, 2024 Feb 21 Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024
Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel Jan 31
Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute Jan 09
Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis Dec 22
Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan Dec 19
Bausch Health: $20bn Debt Is A Mighty Elephant In The Room Nov 30
Consensus EPS estimates fall by 89%, revenue upgraded Nov 09
New major risk - Negative shareholders equity Nov 07
No longer forecast to breakeven Nov 07
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 02
Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet? Nov 01
FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older Oct 21
Consensus EPS estimates fall by 31% Oct 15
Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 13
Consensus EPS estimates fall from profit to US$0.49 loss Oct 01
Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics Sep 24
Price target increased by 11% to US$9.50 Sep 20 Bausch Health Companies Inc. Announces Executive Changes
Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults Sep 14
Executive VP & CFO exercised options to buy US$1.1m worth of stock. Sep 10
Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc Sep 08
Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc Sep 06
Consensus EPS estimates increase from loss to US$0.11 profit Aug 10
Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023 Aug 04
Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022) Aug 04
Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc Jul 27
Is Bausch Health Companies (NYSE:BHC) A Risky Investment? Jul 24
Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 14
Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes Jul 06
New major risk - Financial position Jul 01
Consensus EPS estimates fall by 299% Jun 21
Price target decreased by 29% to US$8.50 Jun 17
What To Do After Bausch Health Stock Plunged By Nearly 9% Again Jun 07
Consensus EPS estimates upgraded to US$0.18 loss May 27
Price target decreased by 8.9% to US$11.92 May 19
Consensus EPS estimates upgraded to US$0.33 loss May 11
Forecast to breakeven in 2025 May 10
First quarter 2023 earnings: EPS misses analyst expectations May 06
Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023 May 05
Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt Apr 18
Forecast breakeven date pushed back to 2025 Apr 18
CEO & Director exercised options to buy US$115k worth of stock. Mar 03
Price target increased by 8.3% to US$13.00 Feb 24
Full year 2022 earnings: EPS misses analyst expectations Feb 24
Investor sentiment improves as stock rises 24% Feb 16
Consensus EPS estimates increase by 214% Feb 03
Bausch Health Companies Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 02
Consensus EPS estimates increase by 214% Jan 29
Investor sentiment improved over the past week Jan 06
Bausch Health: A Basket Case Of A Business Only A Hedge Fund Can Bail Out Dec 30
Bausch Health Companies Inc. Announces Availability of ARAZLOTM Dec 23
Investor sentiment deteriorated over the past week Dec 22
Bausch Health acne lotion Arazlo available in Canada under public drug plans Dec 22
Bausch Health: Things To Consider Before Investing Dec 11
Consensus forecasts updated Nov 25
Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues Nov 10
Third quarter 2022 earnings: EPS exceeds analyst expectations Nov 04
Bausch Health Companies Inc. Revises Consolidated Earnings Guidance for the Full Year 2022 Nov 04
Bausch Health Companies Q3 2022 Earnings Preview Nov 02
Consensus forecasts updated Oct 29 Rendement voor aandeelhouders BHC US Pharmaceuticals US Markt 7D -2.0% 0.6% -0.4% 1Y -1.7% 10.0% 24.8%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: BHC presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 10 % opleverde.
Rendement versus markt: BHC presteerde slechter dan US Market , dat het afgelopen jaar een rendement van 24.8 % opleverde.
Prijsvolatiliteit Is BHC's price volatile compared to industry and market? BHC volatility BHC Average Weekly Movement 6.7% Pharmaceuticals Industry Average Movement 10.5% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stabiele aandelenkoers: BHC heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van BHC is het afgelopen jaar stabiel geweest.
Over het bedrijf Bausch Health Companies Inc. is een gediversifieerd bedrijf in farmaceutische specialiteiten en medische hulpmiddelen in de Verenigde Staten en internationaal. Het bedrijf ontwikkelt, produceert en verkoopt een scala aan producten, voornamelijk op het gebied van gastro-enterologie, hepatologie, neurologie, dermatologie, internationale farmaceutica, receptvrije producten (OTC), esthetische medische hulpmiddelen en ooggezondheid. Het bedrijf is actief in vijf segmenten: Salix, International, Solta Medical, Diversified en Bausch + Lomb.
Meer tonen Bausch Health Companies Inc. Samenvatting Hoe verhouden de winst en inkomsten van Bausch Health Companies zich tot de beurswaarde? BHC fundamentele statistieken Marktkapitalisatie US$2.77b Inkomsten(TTM ) -US$178.00m Inkomsten(TTM ) US$9.47b
0.3x P/S-verhouding
-15.6x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) BHC resultatenrekening (TTM ) Inkomsten US$9.47b Kosten van inkomsten US$2.76b Brutowinst US$6.71b Overige uitgaven US$6.89b Inkomsten -US$178.00m
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -0.48 Brutomarge 70.87% Nettowinstmarge -1.88% Schuld/Eigen Vermogen Verhouding -8,887.2%
Hoe presteerde BHC op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2024/12/24 17:13 Aandelenkoers aan het einde van de dag 2024/12/24 00:00 Inkomsten 2024/09/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten Bausch Health Companies Inc. wordt gevolgd door 46 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Raghuram Selvaraju Aegis Capital Corporation Douglas Tsao Barclays Ardalan Arfaei BMO Capital Markets Equity Research
Toon 43 meer analisten 
